OBJECTIVE: We previously reported that a two week treatment with SKF 38393 (SKF, a dopamine D 1 receptor agonist), plus bromocriptine (BC, a dopamine D 2 receptor agonist) acted synergistically to normalize hyperphagia, body fat, hyperglycaemia and hyperlipidaemia in obaob mice. The present study further investigates the biochemical mechanisms triggered by this drug treatment. DESIGN: Six week old female C57BLa6J obaob mice were divided into three groups and treated for two weeks with either BC and SKF, vehicle (control), or vehicle and pair fed to match the drug-treated group's daily food intake. RESULTS: BCaSKF treatment reduced food consumption by 55%, and treated mice weighed less than either pair fed or ad libitum fed controls after two weeks of treatment. Moreover, oxygen consumption was increased by 2.4-fold and the respiratory quotient (RQ) decreased from 1.23 to 0.96 (indicating a reduction in de novo lipogenesis) by drug treatment relative to ad libitum fed controls, but these parameters were unaffected by pair feeding control mice. The treatment also reduced blood glucose and free fatty acids (FFA) relative to pair fed and ad libitum fed controls. BCaSKF treatment (but not pair feeding) concurrently reduced lipolysis, lipogenic enzyme activities and hepatic gluconeogenic enzyme activities. Treatment also increased hepatic concentrations of glycogen and xylulose-5-phosphate (X-5-P), a key stimulator of glycolysis. Finally, BCaSKF, but not pair feeding, reduced the circulating concentrations of thyroxine and corticosterone, two hormones known to increase lipolysis, lipogenesis and hyperglycaemia. Drug treatment also increased serum dehydroepiandrosterone (DHEA) sulfate concentrations, an inhibitor of body fat store accumulation. CONCLUSION: These ®ndings demonstrate that BCaSKF treatment not only normalizes hyperphagia of obaob mice, but also redirects several metabolic and endocrine activities, independent of its effects on feeding to improve the obese-diabetic syndrome in obaob mice.
Introduction
The obese hyperglycaemic C57BLa6J (obaob) mouse is one of the most extensively studied rodent models of the obesity syndrome. Major characteristics of obaob mice are low oxygen consumption and low body temperature (detected at two weeks of age before obesity is phenotypically expressed). 1 Preobese mice also exhibit hyperinsulinaemia with concomitant increased hepatic lipogenesis before they become hyperglycaemic and obese. 2 This sequence of abnormalities suggests a probable role of the brain in controlling energy intake, storage and expenditure. Indeed obaob mice have multiple central nervous system abnormalities such as hypothalamic increases of noradrenaline (NA) and decreases of dopamine levels.
3 Although the precise relationship between neuroendocrine abnormalities and metabolic dysfunction of obaob mice is still unknown, we have recently reported that co-administration of dopamine D 1 and D 2 receptor agonists (SKF 38393 (SKF) and bromocriptine (BC), respectively) to obaob mice normalized hyperphagia and resulted in reductions of body weight and fat, serum glucose, free fatty acid (FFA) and triglyceride (TG) concentrations. 4 However, the speci®c biochemical mechanisms by which these metabolic effects are manifested remain to be delineated. In the present report, we investigate the biochemical effects of dopamine activation with BC and SKF on energy balance, hepatic glucose production, lipogenesis and lipolysis.
Experimental procedures

Experimental design
Six week old female C57BLa6J obaob mice (average body weight 35 AE 0.3 g) were divided into three groups and treated for two weeks with either BC (10 mgakg of body weight) and SKF (10 mgakg of body weight), vehicle (control) or vehicle and pair fed to match the drug-treated group's daily food intake (n 6 ± 8 miceagroup). All drugs were given one hour after light onset by intraperitoneal (i.p.) injections. Animals were housed one per cage and were held on 12 h daily photoperiods at a temperature of 18 AE 2 C, and allowed to feed ad libitum, except for the pair fed group. Animals were fed standard chow diet Prolab RMH 3000 (Agway, Syracuse, NY). The amount of food given to pair fed animals was calculated from the consumption on the previous day of treated animals and was offered to animals at 11 h after light onset (at the normal nocturnal feeding time for mice). A fourth group of ob lean ( a ) mice was also kept under the same conditions as above, but did not received any vehicle injection. Food consumption was monitored daily, throughout the 14 d treatment period. Between 10 ± 13 d of treatment at 2 ± 5 h after light onset, controls, pair fed, BCaSKF treated and lean mice were placed in airtight Oxymax chambers (Columbus Instrument, Columbus, OH) at 18AE 2 C with an oxygen¯ow of 0.35 Lamin and O 2 consumption and CO 2 production were measured during nine 30 s sampling periods. Animals were allowed to adapt to the metabolic chambers for 30 min. There was no access to water or food during indirect calorimetry measurements. These measurements of metabolic activity were carried out at a daily time period (at 2 ± 5 h after light onset) the same as that at which plasma and tissue samples were harvested at the termination of experiments, so that biochemical parameters measured in tissues and plasma would correlate with the metabolic activity data of the animals. Animals were sacri®ced for the biochemical analyses of plasma and tissues 27 h after the ®nal injection. This time period is approximately 4 h after light onset and several hours after the end of nocturnal feeding. Plasma was collected for the analyses of insulin, glucose, lipids and hormones. Liver and gonadal adipose tissue were collected and either frozen or processed immediately for enzymatic or biochemical analyses and adipocyte isolation.
Blood chemistry
Blood glucose levels were measured with a glucose monitor (Accu-Check Advantage, Boehringer, Indianapolis, IN) and enzymatically using glucose oxidase coupled to peroxidase (Sigma Diagnostics, St Louis, MO). Plasma TG concentration was measured enzymatically using lipoprotein lipase coupled to glycerol kinase (Sigma Diagnostics). Plasma insulin was assayed by radioimmunoassay (RIA) using primary antibody to rat insulin and rat insulin as standard (Linco Research Inc., St Chartes, MO). Plasma corticosterone and thyroxine (T 4 ) were assayed by RIAs using human primary antibodies and human standards (ICN Pharmaceuticals Inc., Cost Mesa, CA). Plasma FFA concentrations were determined by enzymatic colorimetric assay utilizing acyl-CoA synthetase and acyl-CoA oxidase coupled to peroxidase (Wako Chemicals USA, Inc., Richmond, VA). Plasma dehydroepiandrosterone (DHEA) and its sulfate ester (DHEAS) concentrations were determined by RIAs using synthetic or human primary antibodies respectively and human standards (Diagnostic Systems Laboratories, Inc., Webster, TX).
Enzymatic activities
Hepatic and adipose enzymatic activities of fatty acid synthetase (FAS), malic enzyme (ME) and glucose-6-phosphate dehydrogenase (G5PDH) were measured in the isolated cytosolic fraction by spectrophotometric methods. 5, 6 Phosphoenolpyruvate carboxykinase (PEPCK) in liver cytosol was assayed by incorporation of H 14 
CO 3
7 into phosphoenolpyruvate, as previously described. 7 Glucose-6-phosphatase (G6P-ase) activity was determined in freshly isolated liver microsomes as previously described. 8 These enzyme activities were expressed as nmolesaminamg protein.
Xylulose-5-phosphate (X-5-P) was determined in perchloric acid extracts from liver after neutralization to pH 5.0 ± 6.0 with KOH. 9 Liver glycogen content was measured spectrophotometrically using amyloglucosidase and glucose oxidase (Sigma Diagnostics). Lipoprotein lipase (LPL) activity was measured in gonadal fad pads as previously described. 10, 11 Lipolysis in isolated adipose cells Adipose cells were isolated from gonadal fat pads of individual mice by collagenase digestion (1 mgaml). A 10 ± 20% suspension of isolated adipose cells was prepared in Krebs-Ringer phosphate buffer with 20 mM Hepes pH 7.4, 200 nM adenosine, 2.5% BSA and 2 mM glucose. Cells (ca. 30000 cells) were incubated in a ®nal volume of 0.5 ml with adenosine deaminase (1 unitaml, Sigma). Lipolysis was stimulated by isoprenaline (1 mM) for 15 min at 37 C. 12 ± 14 The reaction was terminated by spinning the reaction mixture through dinonyl phtalate oil (ICN Pharmaceuticals Inc., Cost Mesa, CA). The glycerol released into the medium was measured using an enzymatic assay utilizing glycerol kinase coupled with peroxidase (Sigma kit). Adipocyte cell size was measured microscopically and lipid content was measured by lipid extraction. 15 
Statistics
Statistical comparisons between control, pair fed and treated groups were performed by using ANOVA analysis followed by parametric Newman ± Keuls or nonparametric Kruskal ± Wallis tests.
Results
Effects of BCaSKF on food intake, body weight and energy expenditure
BCaSKF treatment substantially decreased food intake (by 55%) compared with control vehicle injected mice (Table 1) . This decrease in feeding occurred within 24 h of the beginning of treatment Dopaminergic agonists improve diabetes in obaob mice PWD Scislowski et al and lasted throughout the two weeks of treatment. Reduced feeding was accompanied by a signi®cant decrease of body weight relative to control (by 7 g) and pair fed (by approx. 4g) mice (Table 1) .
Resting metabolic rate (RMR) was measured by indirect calorimetry in all three groups, as well as in lean littermates. Whereas control and pair fed obese mice had similar rates of oxygen consumption and CO 2 production (which is characteristically low compared to lean mice in the fasting state), oxygen consumption was signi®cantly increased by 2.4-fold and CO 2 production was increased by 2.1-fold in BCaSKF treated mice to values similar to those measured in lean mice. Consequently, the respiratory quotient (RQ) in the treated mice was reduced in comparison to obese control and pair fed mice ( Table 2 ).
Effects of BCaSKF on metabolites and hormones
In parallel with the changes observed in body weight, BCaSKF treatment signi®cantly reduced the blood glucose concentration relative to the concentrations in controls by 72% and pair fed animals by 62% (Table 3) . Plasma TG concentrations were reduced by approx. 30% in pair fed and treated animals, compared to obese controls. However, a drastic decrease (by 70%) of plasma FFA was only observed in treated mice relative to obese controls (Table 3) . High insulin concentrations characteristic of obese control mice, were reduced in pair fed animals by 59% and in treated mice by 39% (P 0.064). Serum corticosterone and T 4 concentrations were reduced by BCaSKF treatment relative to obese control mice by approximately 50%, but were unaffected by pair feeding. Lastly, serum DHEAS concentrations of obese controls were increased by 33% in the drug treated group (Table 3) .
Effects of BCaSKF on adipose tissue and lipogenic enzymes
To investigate further the mechanisms by which de novo lipogenesis is reduced in the treated mice, we assayed key lipogenic enzymatic activities in both liver and gonadal adipose tissue. In the latter, FAS activity was reduced 59% by BCaSKF treatment while in pair fed animals the FAS activity was reduced by only 23% (Table 4 ). In parallel, the activity of G6PDH (an enzyme providing NADPH necessary for fatty acids synthesis) was reduced only in BCaSKF treated mice (by 23%) ( Table 4 ). Similar inhibitory effects of BCaSKF treatment on lipogenic enzymes were observed in the liver. Hepatic malic enzyme as well as FAS activities were reduced by 71% and 60%, respectively. However no signi®cant changes were observed in pair fed mice (Table 4) . Adipocyte size was only reduced (by 51% in drug treated animals, relative to obese controls (Table 4) . Drug treatment reduced adipose LPL activity by 71%, compared to controls, while in pair fed animals the activity was reduced by 35%. Basal and isoprenaline stimulated lipolysis was reduced only in BCaSKF treated animals by approx. 50% (Table 4) .
Effects of BCaSKF on hepatic glucose metabolism
Two key enzymes involved in hepatic gluconeogenesis, PEPCK and G6P-ase were decreased by 25% and (Table 5 ). There were no signi®cant differences in these enzymatic activities between pair fed and control animals. In addition, hepatic activity of G6PDH, the rate limiting step of the pentose cycle, was increased 2-fold by BCaSKF but unaffected by pair feeding. These speci®c enzyme alternations facilitated a 73% increase in the concentration of X-5-P in drug treated mice, relative to controls (Table 5 ). Hepatic glycogen concentrations were increased 2.8-fold in the treated mice, relative to controls, from 99 AE 8 mmoles to 282AE 12 mmoles glycosyl unitsag tissue (P`0.001).
Discussion
The present study has identi®ed several biochemical processes triggered by dopamine D 1 and D 2 receptor agonist treatment, resulting in a reduction of obesity, hyperglycaemia and hyperlipidaemia, independent of their effect to normalize hyperphagia in obaob mice. Lean mice treated with BCaSKF at the same doses as obese mice did not show any adverse effects of the drug treatment; there was no effect on body weight, food consumption or plasma glucose concentration (data not shown). BCaSKF induced reductions in body weight, hyperglycaemia and plasma FFA concentrations were signi®cantly greater than those of pair fed untreated animals ( Table 1, Table 2 ). Contributing factors to the decreased body weight of BCaSKF treated mice relative to pair fed controls are 1) a 2.5-fold increase in oxygen consumption and 2) a reduction of the de novo lipogenesis, as indicated by the decreased RQ of 0.96 relative to that of pair fed (1.33) and ad libitum fed (1.23) controls. The increase in oxygen consumption of BCaSKF treated mice may to some extent be ascribed to its effect to increase locomotor activity in mice. 16 Increased oxygen consumption may also re¯ect energy demands for anabolic processes, such as protein synthesis. BCaSKF treatment has been shown to increase protein mass in these mice 4 as has bromocriptine in hamsters. 17 The relatively high RQ values presented in Table 2 may be the result of the time of the day that the measurements were taken (at 2 ± 5 h after the onset of light). At this time of day, obaob mice have a low metabolic activity. 18 Our measurements, however, are compatible with blood hormone and metabolite analyses taken at this time of the day ( Table 2, Table 3 ). Results are mean values AE s.e.m. Signi®cant differences with respect to control and pair fed group, for *P < 0.01 ND not determined; prot protein. Results are mean values AE s.e.m., signi®cant differences with respect to control group: is *P`0.01 and with respect to pair fed group **P`0.01, ***P`0.05. FFA free fatty acids; prot protein; G6PDH glucose-6-phosphate dehydrogenase.
Dopaminergic agonists improve diabetes in obaob mice
PWD Scislowski et al Caution, however, must be taken when attempting to draw conclusions from these RQ values, inasmuch as increased lipogenesis, diabetes and increased gluconeogenesis; all conditions present in obaob mice, confound absolute interpretation of these values. 19 However, the conclusion that de novo lipogenesis is reduced by BCaSKF based on RQ values is valid under these circumstances (that is, RQ b 1.0) 20 and is further evidenced by drug-induced substantial decreases in hepatic and adipose tissue lipogenic enzyme activities (Table 4) . However, additional mechanisms are operative in the BCaSKF induced reduction in serum FFA. Although it is known that BC is sympatholytic 21 and reduces basal lipolysis in obese hamsters, 22 results of this study further indicate that BCaSKF reduces basal and sympathomimetic stimulated adipocyte lipolysis (Table 4) . Moreover, elevated adipose tissue LPL activity, characteristic of obaob mice, 23 is dramatically reduced by treatment, which will also contribute to reduced serum FFA concentrations. Such multiple biochemical contributions to a reduced serum FFA concentration, induced by BCaSKF (but not by pairfeeding), in turn may support a decrease in plasma FFA stimulated hepatic reesteri®cation to TG. 23 It is important to realize that food restriction, as in the pair fed group, does not decrease (and usually increases) lipid mobilization and serum FFA. However, equivalently decreased caloric intake induced by drug treatment dramatically reduced plasma FFA concentration, indicating that the treatment may not have induced a sense of starvation but rather reset behavioural (that is, feeding) and metabolic processes concurrently.
Information relating to the mechanism by which the treatment reduced the plasma glucose concentration is worthy of speci®c discussion. Drug treatment reduced the activities of the hepatic gluconeogenic enzymes, G6P-ase and PEPCK (Table 5) , during the daily peak in their activities (4 h and 16 h after the onset of light, respectively). During the diurnal portion of the day when mice are not feeding, hepatic glucose output maintains the high plasma glucose concentration. At this time of day (4 h after the onset of light) drug treatment reduced hepatic G6P-ase and increased G6PDH activities, shunting gluconeogenic substrate away from glucose towards the pentose phosphate pathway. This is con®rmed by the substantial increase in the pentose pathway metabolite, X-5-P (Table 5 ). It has been recently demonstrated that an increased hepatic concentration of X-5-P can stimulate phosphofructokinase activity and glycolysis. 24 Inasmuch as plasma FFA have been shown to reduce the hepatic X-5-P concentration, 25 the drug induced reduction in plasma FFA further supports an increase in the hepatic X-5-P concentration. Moreover, the increase in hepatic glucose-6-phosphate, subsequent to the decreased G6P-ase activity, functions to stimulate glycogen synthase 26 and may mediate, in part, the subsequent (12 ± 20 h after the onset of light) increase in liver glycogen content of BCaSKF treated mice relative to controls. These drug induced increases in hepatic glycogen content may also be the consequence of decreased glycogenolysis, which normally peaks prior to 12 h after the onset of light in mice. Nocturnal increases in PEPCK activity, proposed to maintain glucose output during glycogen deposition, 27 are also reduced by the treatment. Such dopaminergic activation, therefore, converts liver glucose metabolism from production to utilization and storage.
These widespread changes in intermediary metabolism correlate well with observed hormonal changes following treatment. Increasing plasma DHEAS levels by exogenous administration, to concentrations similar to that observed by BCaSKF treatment in this study has been shown to reduce body fat concentrations in rats, although the mechanism is unknown. 28 Moreover, the reduction in elevated corticosterone concentrations of obaob mice by adrenalectomy is associated with reductions in hyperphagia, body weight gain, body fat and hyperglycaemia. 29, 30 Corticosterone is a potent stimulator of lipolysis, hepatic glucose output and lipogenesis, therefore, the substantial reduction of plasma corticosterone induced by the treatment (but not by pair feeding) may contribute to the reductions of these biochemical activities. The drug induced reduction in plasma T 4 concentrations seen in association with decreased body weight gain and increased oxygen consumption may seem paradoxical, however, similar associations have previously been reported with interventions which increase dopamine activities (such as BC treatment in the Syrian hamster 17 and dopamine B-hydroxylase knockout mice. 31 Since thyroid hormones induce hepatic lipogenic malic enzyme activity, and increase glucose output and lipolysis, the reduction of T 4 by BCaSKF (but not by pair feeding) correlates well with the above described treatment effects on metabolism.
Although the site(s) of action of BCaSKF to induce these global changes in behaviour, metabolism and endocrine functions is unknown, recent evidence from our laboratory suggests a likely (direct or indirect) target center is the hypothalamus. Dopamine has a strong inhibitory effect on feeding when applied to the perifornical hypothalamic area, where it also functions to antagonize the stimulatory effects of NPY on feeding. 32 We have recently demonstrated that BCaSKF treatment dramatically reduces elevated hypothalamic NPY mRNA and protein concentrations in obaob mice, 33, 34 which may be expected to facilitate a reduction in hyperphagia and an improvement in glucose homeostasis. 35 Furthermore, BC treatment of hamsters normalizes the obese, glucose intolerant condition, while reducing elevated metabolism of noradrenaline and serotonin within the ventromedial hypothalamus, 36 increases in which function to stimulate lipolysis and hepatic glucose output. 37 Such observations are in accord with the BCaSKF effects described herein to reduce lipolysis and hepatic glucose output. In further support of a central target for Dopaminergic agonists improve diabetes in obaob mice PWD Scislowski et al such dopamine agonist treatment is the ®nding that intracerebroventricular administration of BC improves glucose intolerance and insulin resistance, similar to that of systemic administration in hamsters. 38 We are currently investigating the speci®c central nervous system (CNS) activities in¯uenced by BCaSKF which induce its metabolic effects.
Finally it is noteworthy that the observed attenuation of the obese-diabetic syndrome in obaob mice by dopaminergic agonists occurred in the absence of leptin. One may speculate that such a pharmacological intervention may also be effective in leptin resistant obese subjects. Such a possibility is supported by the recent ®nding that BCaSKF treatment reduces obesity in leptin resistant A y mice. 39 
Conclusion
The results of the present study indicate that pharmacological increases in dopaminergic tone, via dopamine D 1 and D 2 agonists, impact on cell and organ level pathophysiology of the obaob mouse to improve the obese-diabetic syndrome. These effects are achieved by 1) increasing energy expenditure; 2) concurrently reducing lipogenesis and lipolysis, allowing for decreased fat stores while simultaneously lowering plasma concentration of FFA; and 3) redirecting hepatic glucose metabolism away from overproduction towards utilization and storage. These drug effects are supported by, but independent of, BCaSKF induced normalization of hyperphagia, inasmuch as pair feeding does not produce the drug induced normalization of energy expenditure, plasma concentrations of FFA and glucose, or reduction in body weight.
